Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Screening for asymptomatic prostate cancer].

A-P Sappino1

  • 1Service d'oncologie, HUG, 1211 Genève 14. andre-pascal.sappino@hcuge.ch

Revue Medicale Suisse
|June 17, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The CEACAM1 tumor suppressor is an ATM and p53-regulated gene required for the induction of cellular senescence by DNA damage.

Oncogenesis·2013
Same author

[Ovarian cancer screening: recommendations for clinical pratice].

Revue medicale suisse·2010
Same author

Socio-demographic predictors of high support needs in newly diagnosed breast cancer patients.

European journal of cancer care·2010
Same author

[Surveillance following curative therapy for breast cancer].

Revue medicale suisse·2008
Same author

[Complementary medicine use in oncology patients].

Revue medicale suisse·2008
Same author

Recent increase of breast cancer incidence among women under the age of forty.

British journal of cancer·2007
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

[Erythema multiforme : target deciphering].

Revue medicale suisse·2026
See all related articles

Prostate cancer screening using PSA tests is widely promoted but lacks evidence of reducing mortality. Many detected cancers are slow-growing and don't require aggressive treatment, necessitating better risk selection methods.

Area of Science:

  • Urology
  • Oncology
  • Preventive Medicine

Context:

  • Widespread prostate cancer screening in asymptomatic individuals is driven by high disease prevalence and accessible PSA testing.
  • Current screening practices lack robust evidence supporting a reduction in mortality rates through population-wide detection and treatment.
  • The benefits of radical treatment for screen-detected, preclinical cancers remain unproven and may lead to overtreatment.

Purpose:

  • To critically appraise the evidence supporting prostate cancer screening in asymptomatic men.
  • To evaluate the impact of population-based screening and radical treatment on prostate cancer mortality.
  • To highlight the need for improved methods to select high-risk patients for therapeutic intervention.

Summary:

  • Formal evidence demonstrating that population-based prostate cancer screening reduces mortality is currently lacking.

Related Experiment Videos

  • A significant proportion of cancers detected through screening exhibit indolent behavior, questioning the justification for aggressive therapeutic approaches with substantial morbidity.
  • Further research into tumor progression mechanisms is essential for developing biomarkers to identify patients who would truly benefit from radical treatments.

    • Impact:

    • Challenges the current enthusiasm for widespread prostate cancer screening in asymptomatic individuals.
    • Suggests a shift towards more targeted screening strategies based on biological risk stratification.
    • Emphasizes the need for improved diagnostic tools to differentiate between indolent and aggressive prostate cancers, thereby avoiding overtreatment and associated complications.